Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 3Thoracic 2Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 214Lung Neoplasms 79Triple Negative Breast Neoplasms 67Breast Neoplasms 67Ovarian Neoplasms 56Squamous Cell Carcinoma of Head and Neck 49Small Cell Lung Carcinoma 47Fallopian Tube Neoplasms 37Endometrial Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 28Neoplasm Metastasis 28Head and Neck Neoplasms 24Prostatic Neoplasms 20Carcinoma 19Esophageal Neoplasms 18Urinary Bladder Neoplasms 16Colorectal Neoplasms 16Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Squamous Cell 14Esophageal Squamous Cell Carcinoma 13Brain Neoplasms 12Stomach Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Mouth Neoplasms 9Laryngeal Neoplasms 9Carcinoma, Ovarian Epithelial 9

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Carboplatin × 1 year × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡